Good metabolic control using tacrolimus-based immunosuppressants in primary cadaveric renal transplantation in Chinese - a preliminary report
Publication in refereed journal


Times Cited
Web of Science3WOS source URL (as at 17/11/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractMetabolic complications are common with tacrolimus therapy. Recent evidence suggests that there is ethnical variability in the side-effect profile of tacrolimus. We performed an open-label study to examine the metabolic profile of tacrolimus-based immunosuppressive therapy in 10 consecutive adult Chinese patients after cadaveric renal transplantation. One case withdrew because of parvovirus infection. The mean age of the remaining nine cases was 33 +/- 2.9 yr. Mean tacrolimus whole blood trough level at 0 and 12 months were 11.4 +/- 1.8 and 7.0 +/- 0.7 ng/mL, respectively. The dosage at corresponding time points were 0.31 +/- 0.001 and 0.10 +/- 0.003 mg/kg, respectively. We found no difference in lipid profile, blood pressure control, and most importantly, fasting glucose level, before and I yr after tacrolimus therapy. Standard 75-g oral glucose tolerance test and whole blood HbA1c level were normal in all patients. Our preliminary data suggest good short-term safety among Chinese renal transplantation recipients after tacrolimus-based immunosuppressants, with a very low incidence of hyperglycemia, hypertension and dyslipidemia. The long-term implications and the underlying explanation for this ethnical difference require further investigations.
All Author(s) ListChow KM, Szeto CC, Li PKT
Journal nameClinical Transplantation
Year2002
Month2
Day1
Volume Number16
Issue Number1
PublisherBLACKWELL MUNKSGAARD
Pages39 - 42
ISSN0902-0063
LanguagesEnglish-United Kingdom
KeywordsChinese; metabolic control; post-transplant diabetes mellitus; tacrolimus
Web of Science Subject CategoriesSurgery; SURGERY; Transplantation; TRANSPLANTATION

Last updated on 2020-18-11 at 00:24